Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open label extension study of fenfluramine add-on therapy in myoclonic astatic epilepsy (Doose syndrome)
2020-002238-34Phase 2Active
- Sponsor
- University Hospital Schleswig-Holstein
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenfluramine in myoclonic astatic epilepsy (MAE) and epilepsy, sponsored by University Hospital Schleswig-Holstein. Primary endpoints: Long-term safety of fenfluramine add-on therapy and Long-term efficacy of fenfluramine add-on therapy. Started Dec 2020; status: active.
02
Drugs
fenfluramine
03
Conditions
myoclonic astatic epilepsy (MAE)epilepsy
Beyond the preview
Go deeper on 2020-002238-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002238-34.